Proton radiation for inoperable soft tissue sarcoma
Part of Cancer clinical trials.
This trial studies a high-dose, shortened course of proton beam radiation for people with soft tissue sarcoma that cannot be removed by surgery. It aims to improve tumor control while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed diagnosis of soft tissue sarcoma (including GIST)
- Your tumor can be measured on scans
- You are able to care for yourself (ECOG score 0, 1, or 2)
- Your doctor expects you to live at least 2 years if the cancer has spread
- You have not had radiation to the same area before
- You do not have a pacemaker or implanted defibrillator
- You have not had chemotherapy, targeted therapy, or immunotherapy within 14 days before starting radiation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter, 3-week course of radiation therapy (using protons or standard X-rays) given before surgery for localized soft tissue sarcoma. It aims to see if this approach is safe and effective for treating the tumor while reducing side effects.
This trial tests a newer way of giving radiation (spatially fractionated) compared to standard radiation for people with large soft tissue sarcomas. It aims to see if the new method works better.
This trial tests a combination of radiation therapy and two drugs (anlotinib and penpulimab) given before surgery for soft tissue sarcoma. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new way of giving radiation therapy (called spatially fractionated radiotherapy) combined with a treatment strategy called PraG (pembrolizumab and granulocyte-macrophage colony-stimulating factor) for people with soft tissue sarcoma that cannot be removed or has spread. The goal is to see if the combination can help shrink or control the cancer.
This trial studies whether adding a chemotherapy medicine called trabectedin to targeted radiation can help control certain soft tissue sarcomas. It focuses on specific cancer types and locations, aiming to shrink tumors while keeping radiation safe for nearby healthy organs.
This trial tests a new approach for people with a rare type of cancer called retroperitoneal sarcoma, which grows in the back of the belly. It combines a short course of radiation and an immunotherapy drug before surgery, aiming to shrink the tumor and improve the chances of successful removal.
Hear when a new Soft Tissue Sarcoma Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.